FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Accumulating studies suggest that overnutrition-associated obesity may lead to development of type 2 diabetes mellitus and metabolic syndromes (MetS). MetS and its components are important risk factors of mild cognitive impairment, age-related cognitive decline, vascular dementia, and Alzheimer’s disease. It has been recently proposed that development of a disease-course modification strategy toward early and effective risk factor management would be clinically significant in reducing the risk of metabolic disorder-initiated cognitive decline. In the present study, we propose that fibroblast growth factor 21 (FGF21) is a novel candidate for the disease-course modification approach. Using a high-fat diet (HFD) consumption-induced obese mouse model, we tested our hypothesis that recombinant human FGF21 (rFGF21) administration is effective for improving obesity-induced cognitive dysfunction and anxiety-like behavior, by its multiple metabolic modulation and anti-pro-inflammation actions. Our experimental findings support our hypothesis that rFGF21 is protective to HFD-induced cognitive impairment, at least in part by metabolic regulation in glucose tolerance impairment, insulin resistance, and hyperlipidemia; potent systemic pro-inflammation inhibition; and improvement of hippocampal dysfunction, particularly by inhibiting pro-neuroinflammation and neurogenesis deficit. This study suggests that FGF21 might be a novel molecular target of the disease-course-modifying strategy for early intervention of MstS-associated cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212 · cited 1×
“Furthermore, the low degree of systemic pro-inflammation in adipose tissue circulation and neuroinflammation in the brain hippocampus may be one of the connections between obesity/diabetes and neurocognitive dysfunction [2, 9, 10]; thus, new therapeutic approaches have been proposed to modulate metabolic dysfunction a…”
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945 · cited 1×
“cules with wide ranging functions in development, cell proliferation, and wound healing [15].”
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665 · cited 1×
“functions are typical features of the metabolic syndromes and may be associated with a pro-inflammatory gradient, which in part may originate in the adipose tissue itself and directly affect the endothelium and brain functions [59].”
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Makki, K., Froguel, P., & Wolowczuk, I. (2013) · ISRN Inflammation · doi:10.1155/2013/139239 · Cited by 1,085
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 1×
“FGF21 exerts potent and multipleiotropic metabolic actions [22, 23], and these benefits have been translated from rodents to obese humans with type 2 diabetes without causing side effects such as mitogenicity and hypoglycemia [24, 25].”
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · cited 1×
“The elevation of FGF21 could be a compensatory protective response to underlyingmetabolic stress or might be due to impaired FGF21 signaling of βKlotho and FGFR downregulation [61], called FGF21 resistance that implies the need for supraphysiological doses of rFGF21 to achieve therapeutic efficacy [19, 22, 62].”
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545
Deckers, K., van Boxtel, M. P. J., Schiepers, O. J. G., de Vugt, M., Muñoz Sánchez, J. L., Anstey, K. J., Brayne, C., Dartigues, J.-F., Engedal, K., Kivipelto, M., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4245 · Cited by 534
Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., Asada, M., Komi-Kuramochi, A., Oka, S., & Toru, T. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0313 · Cited by 345
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · cited 1×
“Although the FGF21-mediated signaling pathways remain unclear, the mechanisms of rFGF21 therapeutic effects may involve beneficial metabolic regulation [28], antiinflammation [29, 30], antioxidative stress [31–33], inhibition of advanced glycation end products formation [31], and promotion of tissue repair [27, 34, 35…”
Liang, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S. R., Triggle, C. R., Ding, H., Lam, K. S. L., & Xu, A. (2014) · Diabetes · doi:10.2337/db14-0541 · Cited by 299
The fasting polypeptide FGF21 can enter brain from blood
Hsuchou, H., Pan, W., & Kastin, A. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.007 · Cited by 280 · cited 12×
“The results indicated that HFD mice were FGF21 resistant, characterized by higher FGF21 concentration in the blood but not in the CSF and brain hippocampus tissues. rFGF21 was able to cross the BBB and activate its receptor FGFR1 in the hippocampus. rFGF21 Suppresses Microglia Activation and Pro-inflammatory Cytokine…”
MethodInfluentialNeuroinflammation and neurodegeneration in overnutrition-induced diseases
Cai, D. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.003 · Cited by 256 · cited 1×
“Chronic systemic inflammation initiated in white adipose tissue plays a crucial role in the development of obesity-related insulin resistance and neuroinflammation [2, 48, 49].”
André, C., Dinel, A.-L., Ferreira, G., Layé, S., & Castanon, N. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.03.012 · Cited by 241
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
Hale, C., Chen, M. M., Stanislaus, S., Chinookoswong, N., Hager, T., Wang, M., Véniant, M. M., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2010-1262 · Cited by 185 · cited 1×
“The elevation of FGF21 could be a compensatory protective response to underlyingmetabolic stress or might be due to impaired FGF21 signaling of βKlotho and FGFR downregulation [61], called FGF21 resistance that implies the need for supraphysiological doses of rFGF21 to achieve therapeutic efficacy [19, 22, 62].”
Kim, K. H., & Lee, M.-S. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.245 · Cited by 146 · cited 3×
“One of the most unique biological features of FGF21 is its ability to exert potent and multipleiotropic metabolic effects [22, 23].”
FGF21 and Cardiac Physiopathology
Planavila, A., Redondo-Angulo, I., & Villarroya, F. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00133 · Cited by 123
Yu, Y., Bai, F., Wang, W., Liu, Y., Yuan, Q., Qu, S., Zhang, T., Tian, G., Li, S., Li, D., et al. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.03.020 · Cited by 119 · cited 1×
“Although the FGF21-mediated signaling pathways remain unclear, the mechanisms of rFGF21 therapeutic effects may involve beneficial metabolic regulation [28], antiinflammation [29, 30], antioxidative stress [31–33], inhibition of advanced glycation end products formation [31], and promotion of tissue repair [27, 34, 35…”
Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis
Markan, K. R., & Potthoff, M. J. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.021 · Cited by 103 · cited 1×
“Very interestingly, several FGFs have been linked to metabolism regulation [17].”
Effects of fibroblast growth factor 21 on the heart
Tanajak, P., Chattipakorn, S. C., & Chattipakorn, N. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0289 · Cited by 72 · cited 1×
“Although the FGF21-mediated signaling pathways remain unclear, the mechanisms of rFGF21 therapeutic effects may involve beneficial metabolic regulation [28], antiinflammation [29, 30], antioxidative stress [31–33], inhibition of advanced glycation end products formation [31], and promotion of tissue repair [27, 34, 35…”
Cited by
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170
Jena, P. K., Sheng, L., Di Lucente, J., Jin, L., Maezawa, I., & Wan, Y. Y. (2018) · The FASEB Journal · doi:10.1096/fj.201700984rr · Cited by 134
“In a high-fat, diet-induced obese mouse model, recombinant human FGF21,which is used to treat obesity and diabetes, can improve cognitive dysfunction, restore synaptic plasticity, and ameliorate anxiety-like behavior (63, 64).”
BackgroundHigh-fat diet causes psychiatric disorders in mice by increasing Proteobacteria population
Jeong, M.-Y., Jang, H.-M., & Kim, D.-H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.006 · Cited by 110
Physical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Metadata
- Authors
- Wang, Q., Yuan, J., Yu, Z., Lin, L., Jiang, Y., Cao, Z., Zhuang, P., Whalen, M. J., Song, B., Wang, X.-J., Li, X., Lo, E. H., Xu, Y., & Wang, X.
- Venue
- Molecular Neurobiology
- Published
- 2017-07-15
- Volume
- 55
- Issue
- 6
- Pages
- 4702-4717
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2735844318
- Cited by
- 156
- References
- 23
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.